全球中樞神經系統（CNS）生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計中樞神經系統 (CNS) 生物標記市場將從 2025 年的 71.4 億美元成長到 2034 年的 150.1 億美元，2026 年至 2034 年的複合年成長率為 8.61%。

隨著神經系統和精神疾病研究的活性化，中樞神經系統生物標記市場持續擴張。生物標記能夠提供疾病進展、治療效果和早期診斷的可測量指標，例如阿茲海默症、帕金森氏症、癲癇和多發性硬化症等疾病。中樞神經系統疾病盛行率的上升、藥物研發投入的增加以及對個人化醫療的需求，正在推動臨床實踐、製藥業和研究機構對生物標記的應用。

技術創新正在推動市場成長。先進的成像技術、分子、遺傳和蛋白質體學技術能夠精準地辨識和監測生物標記。人工智慧驅動的分析、高通量篩檢以及與實驗室晶片平台的整合，正在提升預測性診斷、臨床試驗效率和患者分層水準。多重生物標記檢測可以同時評估多個通路，有助於改善治療決策和藥物研發成果。

預計未來成長將主要由研發投入增加、人口老化以及精準醫療舉措的擴展所驅動。北美和歐洲憑藉其成熟的臨床研究基礎設施主導市場，而亞太地區則在不斷擴張的製藥和神經科學研究中心的推動下，正經歷快速的市場應用。學術機構、生物技術公司和製藥公司之間的合作正在加速生物標記的發現和檢驗。中樞神經系統（CNS）生物標記有望成為神經系統疾病治療的重要工具，從而實現早期療育、個人化治療並改善患者預後。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球中樞神經系統（CNS）生物標記市場：依生物標記類型分類

• 市場分析、洞察與預測
• 安全生物標記
• 療效生物標記
• 驗證生物標記
• 其他生物標記

第5章 全球中樞神經系統（CNS）生物標記市場：依應用分類

• 市場分析、洞察與預測
• 疾病診斷
• 藥物發現與開發
• 個人化醫療
• 其他用途

第6章 全球中樞神經系統（CNS）生物標記市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院和診所
• 診斷檢查室
• 學術研究機構
• 其他最終用戶

第7章 全球中樞神經系統（CNS）生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • BioMerieux
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche Ltd
  • G-Biosciences
  • Illumina Inc
  • Merck KGaA
  • Myriad Genetics Inc
  • Novartis AG
  • PerkinElmer Inc
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc

The Central Nervous System (CNS) Biomarkers Market size is expected to reach USD 15.01 Billion in 2034 from USD 7.14 Billion (2025) growing at a CAGR of 8.61% during 2026-2034.

The CNS biomarkers market is expanding as neurological and psychiatric disorder research intensifies. Biomarkers provide measurable indicators of disease progression, therapeutic response, and early diagnosis in conditions such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. Rising prevalence of CNS disorders, investment in drug development, and demand for personalized therapies are driving adoption across clinical, pharmaceutical, and research settings.

Technological innovation is fueling market growth. Advanced imaging, molecular, genetic, and proteomic techniques enable precise biomarker identification and monitoring. Integration with AI-driven analytics, high-throughput screening, and lab-on-a-chip platforms enhances predictive diagnostics, clinical trial efficiency, and patient stratification. Multiplex biomarker panels allow simultaneous assessment of multiple pathways, improving therapeutic decision-making and drug development outcomes.

Future growth is expected from increasing R&D investment, aging populations, and expansion of precision medicine initiatives. North America and Europe dominate due to mature clinical research infrastructure, while Asia-Pacific is witnessing rapid adoption fueled by expanding pharmaceutical and neuroscience research hubs. Collaborations between academic institutions, biotech firms, and pharmaceutical companies are accelerating biomarker discovery and validation. CNS biomarkers are poised to become integral tools in neurotherapeutics, enabling early intervention, personalized treatment, and improved patient outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Biomarker Type

• Safety Biomarker
• Efficacy Biomarker
• Validation Biomarker
• Other Biomarkers

By Application

• Disease Diagnosis
• Drug Discovery And Development
• Personalized Medicines
• Other Applications

By End-Use

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Other End-Users

COMPANIES PROFILED

• bioMerieux, BioRad Laboratories Inc, F HoffmannLa Roche Ltd, GBiosciences, Illumina Inc, Merck KGaA, Myriad Genetics Inc, Novartis AG, PerkinElmer Inc, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY BIOMARKER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Biomarker Type
• 4.2. Safety Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Efficacy Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Validation Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Disease Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Discovery And Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Personalized Medicines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Biomarker Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Biomarker Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Biomarker Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Biomarker Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Biomarker Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 BioMerieux
  • 9.2.2 Bio-Rad Laboratories Inc
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 G-Biosciences
  • 9.2.5 Illumina Inc
  • 9.2.6 Merck KGaA
  • 9.2.7 Myriad Genetics Inc
  • 9.2.8 Novartis AG
  • 9.2.9 PerkinElmer Inc
  • 9.2.10 Siemens Healthineers AG
  • 9.2.11 Sysmex Corporation
  • 9.2.12 Thermo Fisher Scientific Inc